vimizim
biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - muukopolysakkaridoosi iv - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - vimizim on tarkoitettu hoito mucopolysaccharidosis, kirjoita iva (morquion a oireyhtymä, mps iva) potilaiden kaikenikäisille.
vyndaqel
pfizer europe ma eeig - tafamidis - amyloidoosi - muut hermoston huumeet - vyndaqel on tarkoitettu kohtelu transthyretin amyloidoosi aikuispotilailla, joilla on 1 vaihe oireenmukaista polyneuropatia lykätä reuna neurologinen heikkeneminen.
livogiva
theramex ireland limited - teriparatidi - osteoporoosi - kalsiumin homeostaasi - livogiva is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.
skysona
bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - muut hermoston huumeet - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.
byooviz
samsung bioepis nl b.v. - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - silmätautien - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatiset kasvaimet - endokriinihoito - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
sondelbay
accord healthcare s.l.u. - teriparatidi - osteoporoosi - kalsiumin homeostaasi - sondelbay is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.
ximluci
stada arzneimittel ag - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.